share_log

Goldman Sachs Maintains Buy on Veracyte, Lowers Price Target to $28

Moomoo 24/7 ·  Apr 15 10:33

Goldman Sachs analyst Matthew Sykes maintains Veracyte (NASDAQ:VCYT) with a Buy and lowers the price target from $32 to $28.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment